AU2014235779B2 - Metadichol liquid and gel nanoparticle formulations - Google Patents
Metadichol liquid and gel nanoparticle formulations Download PDFInfo
- Publication number
- AU2014235779B2 AU2014235779B2 AU2014235779A AU2014235779A AU2014235779B2 AU 2014235779 B2 AU2014235779 B2 AU 2014235779B2 AU 2014235779 A AU2014235779 A AU 2014235779A AU 2014235779 A AU2014235779 A AU 2014235779A AU 2014235779 B2 AU2014235779 B2 AU 2014235779B2
- Authority
- AU
- Australia
- Prior art keywords
- disease
- week
- subject
- levels
- patients
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Inorganic Chemistry (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Nanotechnology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Composite Materials (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Physics & Mathematics (AREA)
- Cardiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361794490P | 2013-03-15 | 2013-03-15 | |
| US61/794,490 | 2013-03-15 | ||
| PCT/US2014/023777 WO2014150609A1 (en) | 2013-03-15 | 2014-03-11 | Metadichol r liquid and gel nanoparticle formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2014235779A1 AU2014235779A1 (en) | 2015-09-03 |
| AU2014235779B2 true AU2014235779B2 (en) | 2015-11-26 |
Family
ID=51530033
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2014235779A Active AU2014235779B2 (en) | 2013-03-15 | 2014-03-11 | Metadichol liquid and gel nanoparticle formulations |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9006292B2 (https=) |
| EP (1) | EP2968209B1 (https=) |
| JP (2) | JP5996146B2 (https=) |
| KR (1) | KR101700949B1 (https=) |
| CN (1) | CN105188687B (https=) |
| AU (1) | AU2014235779B2 (https=) |
| BR (1) | BR112015011379B1 (https=) |
| CA (1) | CA2894370C (https=) |
| DK (1) | DK2968209T3 (https=) |
| HK (1) | HK1212247A1 (https=) |
| MX (1) | MX359686B (https=) |
| RU (2) | RU2631600C2 (https=) |
| SG (1) | SG11201506430XA (https=) |
| WO (1) | WO2014150609A1 (https=) |
| ZA (1) | ZA201505436B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3356415B1 (en) | 2015-09-29 | 2024-05-01 | Amgen Inc. | Asgr inhibitors for reduzing cholesterol levels |
| HUE069400T2 (hu) * | 2019-09-30 | 2025-03-28 | Tolmar International Ltd | Folyékony polimer készítmények és rendszerek peptidek mint hatóanyagok nyújtott leadására |
| US11554087B2 (en) | 2020-11-05 | 2023-01-17 | The Gillette Company Llc | Shaving aid comprising an antioxidant |
| CN114699537B (zh) * | 2022-03-07 | 2024-06-21 | 西安交通大学医学院第一附属医院 | 一种改善缺氧增敏pd-1抗体疗效的ros响应抗癌药物 |
| EP4618972A1 (en) * | 2022-11-18 | 2025-09-24 | Phytoceutical Limited | Biofilm treatment |
| CN118011012B (zh) * | 2024-02-19 | 2025-01-21 | 中国科学院昆明动物研究所 | LL-37-ApoB-100生物标志物及其应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030198616A1 (en) * | 2002-04-23 | 2003-10-23 | Combe Incorporated | Moisturizing skin gel and method |
| US20100215752A1 (en) * | 2009-02-23 | 2010-08-26 | NanoRx, Inc. | Policosanol nanoparticles |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4670471A (en) * | 1981-11-03 | 1987-06-02 | Clark Lealand L | Treatment for inflammatory skin disease |
| US20090191288A1 (en) | 1996-02-12 | 2009-07-30 | Squires Meryl J | Composition to Treat Herpes, Pseudomonas, Staph, Hepatitis and Other Infectious Diseases |
| JP4533134B2 (ja) * | 2002-06-10 | 2010-09-01 | エラン ファーマ インターナショナル，リミティド | ナノ粒子ポリコサノール製剤および新規なポリコサノールの組合せ |
| ITMI20031313A1 (it) * | 2003-06-27 | 2004-12-28 | Indena Spa | Associazioni di agenti vasoprotettori e formulazioni che li contengono. |
| US7217546B1 (en) * | 2003-07-01 | 2007-05-15 | Sami Labs Ltd | Commercially viable process for high purity of fatty alcohol C24 to C36 and its cosmetic application for skin hair and nails |
| US20050074443A1 (en) * | 2003-10-03 | 2005-04-07 | Treadwell Benjamin V. | Methods of attenuating autoimmune disease and compositions useful therefor |
| WO2008070602A2 (en) * | 2006-12-04 | 2008-06-12 | Smithkline Beecham Corporation | Topical pharmaceutical composition |
| WO2011064631A1 (en) * | 2009-10-02 | 2011-06-03 | Foamix Ltd. | Surfactant-free, water-free, foamable compositions and breakable foams and their uses |
| WO2012027159A1 (en) * | 2010-08-23 | 2012-03-01 | NanoRx, Inc. | Policosanol nanoparticles |
| US20130045179A1 (en) | 2011-08-15 | 2013-02-21 | Mihai Ciustea | Combination therapy and methods for treatment and prevention of hyperproliferative diseases |
-
2014
- 2014-03-11 KR KR1020157020035A patent/KR101700949B1/ko active Active
- 2014-03-11 US US14/205,243 patent/US9006292B2/en active Active
- 2014-03-11 JP JP2016501340A patent/JP5996146B2/ja active Active
- 2014-03-11 CN CN201480016205.7A patent/CN105188687B/zh active Active
- 2014-03-11 BR BR112015011379-6A patent/BR112015011379B1/pt active IP Right Grant
- 2014-03-11 SG SG11201506430XA patent/SG11201506430XA/en unknown
- 2014-03-11 RU RU2015143270A patent/RU2631600C2/ru active
- 2014-03-11 DK DK14770019.9T patent/DK2968209T3/da active
- 2014-03-11 EP EP14770019.9A patent/EP2968209B1/en active Active
- 2014-03-11 RU RU2017116682A patent/RU2736752C2/ru active
- 2014-03-11 MX MX2015008676A patent/MX359686B/es active IP Right Grant
- 2014-03-11 AU AU2014235779A patent/AU2014235779B2/en active Active
- 2014-03-11 WO PCT/US2014/023777 patent/WO2014150609A1/en not_active Ceased
- 2014-03-11 HK HK16100350.6A patent/HK1212247A1/xx unknown
- 2014-03-11 CA CA2894370A patent/CA2894370C/en active Active
-
2015
- 2015-07-28 ZA ZA2015/05436A patent/ZA201505436B/en unknown
-
2016
- 2016-07-12 JP JP2016137526A patent/JP6346918B2/ja active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030198616A1 (en) * | 2002-04-23 | 2003-10-23 | Combe Incorporated | Moisturizing skin gel and method |
| US20100215752A1 (en) * | 2009-02-23 | 2010-08-26 | NanoRx, Inc. | Policosanol nanoparticles |
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201506430XA (en) | 2015-09-29 |
| JP2017008057A (ja) | 2017-01-12 |
| EP2968209A4 (en) | 2016-11-02 |
| MX2015008676A (es) | 2016-04-25 |
| RU2015143270A (ru) | 2017-04-27 |
| RU2017116682A (ru) | 2018-10-23 |
| KR20150127575A (ko) | 2015-11-17 |
| US9006292B2 (en) | 2015-04-14 |
| CA2894370C (en) | 2016-01-12 |
| EP2968209B1 (en) | 2020-12-16 |
| JP5996146B2 (ja) | 2016-09-21 |
| RU2017116682A3 (https=) | 2020-06-03 |
| JP2016512827A (ja) | 2016-05-09 |
| CA2894370A1 (en) | 2014-09-25 |
| BR112015011379B1 (pt) | 2022-10-11 |
| JP6346918B2 (ja) | 2018-06-20 |
| WO2014150609A1 (en) | 2014-09-25 |
| AU2014235779A1 (en) | 2015-09-03 |
| ZA201505436B (en) | 2016-07-27 |
| RU2736752C2 (ru) | 2020-11-19 |
| MX359686B (es) | 2018-10-05 |
| RU2631600C2 (ru) | 2017-09-25 |
| HK1212247A1 (en) | 2016-06-10 |
| CN105188687B (zh) | 2018-05-01 |
| CN105188687A (zh) | 2015-12-23 |
| DK2968209T3 (da) | 2021-01-04 |
| EP2968209A1 (en) | 2016-01-20 |
| BR112015011379A2 (https=) | 2017-08-22 |
| US20140275285A1 (en) | 2014-09-18 |
| KR101700949B1 (ko) | 2017-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wu et al. | Turmeric‐derived nanoparticles functionalized aerogel regulates multicellular networks to promote diabetic wound healing | |
| AU2014235779B2 (en) | Metadichol liquid and gel nanoparticle formulations | |
| Zhang et al. | Cyclodextrin-coordinated liposome-in-gel for transcutaneous quercetin delivery for psoriasis treatment | |
| Zhuo et al. | Targeted modulation of intestinal epithelial regeneration and immune response in ulcerative colitis using dual-targeting bilirubin nanoparticles | |
| Eviö et al. | Effects of alendronate and hormone replacement therapy, alone and in combination, on bone mass and markers of bone turnover in elderly women with osteoporosis | |
| CN104159594A (zh) | 用于皮肤病治疗的凯莫瑞c15肽的局部制剂 | |
| García et al. | Multi-kinetic release of benznidazole-loaded multiparticulate drug delivery systems based on polymethacrylate interpolyelectrolyte complexes | |
| de Lima Nunes et al. | Curzerene antileishmania activity: Effects on Leishmania amazonensis and possible action mechanisms | |
| de Barros et al. | Liposomes containing an ASP49-phospholipase A2 from Bothrops jararacussu snake venom as experimental therapy against cutaneous leishmaniasis | |
| JP2013515019A (ja) | カルシポトリオール一水和物ナノクリスタル | |
| Papp et al. | The safety and tolerability of topically delivered kynurenic acid in humans. A phase 1 randomized double-blind clinical trial | |
| AU2017283511B2 (en) | Formulation for use in the treatment of uremic pruritus | |
| US8673280B2 (en) | Pharmaceutical composition for intracellar acidification with cis-urocanic acid | |
| EP2488198A2 (en) | Treatment and diagnosis of inflammatory disorders | |
| Mavuso et al. | In vitro, ex vivo, and in vivo evaluation of a dual pH/redox responsive nanoliposomal sludge for transdermal drug delivery | |
| Cao et al. | Tea-derived extracellular vesicles-mediated PDRN delivery activates cAMP-HIF-1α to restore intestinal homeostasis in inflammatory bowel disease | |
| Schneider et al. | Half-life extension of the HIV-fusion inhibitor peptide TRI-1144 using a novel linker technology | |
| CN108904445A (zh) | 钙泊三醇纳米悬浮液 | |
| Purwanto et al. | Anti-inflammatory Effect and Physical Stability Test of Nanoemulgel Containing Marjoram (Origanum majorana L.) Essential Oil | |
| DK2878306T3 (en) | MODIFIED PEPTIDE, CB RECEPTOR LIGAND, KIT, IN VITRO PROCEDURE FOR EVALUATION OF CB RECEPTOR BINDINGS, APPLICATIONS, PHARMACEUTICAL COMPOSITION FOR MODULATING CBRECEPTOR ACTIVITY | |
| TWI740342B (zh) | 胜肽ＣＰＰｅｃｐ二聚體用於治療皮膚炎之用途 | |
| Liu et al. | Hyaluronic acid-based ROS-responsive nanomicelles for curcumin delivery in the treatment of LPS-induced acute kidney injury | |
| TWI655203B (zh) | 新穎胜肽、含有該胜肽之組合物及其用途 | |
| JP2021070661A (ja) | Ｔｓｌｐ遺伝子発現抑制用、ｉｌ−３３遺伝子発現抑制用、又はフィラグリン産生促進用組成物 | |
| Zucker et al. | Prostaglandin E analogue inhibition of intrinsic factor release |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |